STOCK TITAN
  1. Home
  2. Sec-filings
  3. otlk
  4. [8-K] Outlook Therapeutics, Inc. Reports Material Event

Outlook Therapeutics (OTLK) plans $55.0M stock and warrant offering with insider buy-in

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. entered into an Underwriting Agreement with Piper Sandler & Co. and BTIG, LLC for a public offering of 55,555,556 shares of common stock together with accompanying warrants to purchase up to an aggregate of 55,555,556 shares, at a combined public offering price of $0.99 per share and accompanying warrant. The company granted underwriters a 30‑day option to purchase up to 8,333,333 additional shares and/or warrants; the underwriters exercised this option for the additional warrants. Estimated gross proceeds are approximately $55.0 million before underwriting discounts, commissions and expenses and assuming no warrant exercises.

Each warrant is immediately exercisable at $1.10 per share and expires five years from issuance, subject to ownership limits of 4.99%, 9.99% or 19.99% of outstanding common stock. GMS Ventures and Investments, the largest stockholder, and senior executives, including the CEO and CFO, participated in the offering by purchasing common stock and accompanying warrants.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Shares offered 55,555,556 shares of common stock Primary public offering with accompanying warrants
Accompanying warrants 55,555,556 warrants Warrants to purchase common stock issued with each share
Public offering price $0.99 per share and accompanying Warrant Combined public offering price for each share-warrant unit
Estimated gross proceeds $55.0 million Before underwriting discounts, commissions and expenses, excluding warrant exercises
Underwriters’ option size 8,333,333 additional shares and/or warrants 30-day option; exercised for additional warrants only
Warrant exercise price $1.10 per share Initial exercise price, subject to customary adjustments
Ownership limits 4.99%, 9.99% or 19.99% Beneficial ownership caps on warrant exercise, adjustable with 61 days’ notice
Largest stockholder participation 2,525,252 shares and warrants Purchased by GMS Ventures and Investments in the offering
Underwriting Agreement financial
"entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co."
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
prospectus supplement regulatory
"and a prospectus supplement thereunder."
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
registration statement on Form S-3 regulatory
"pursuant to the Company’s effective registration statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
Nasdaq Listing Rule 5635(b) regulatory
"change of control under Nasdaq Listing Rule 5635(b) or any successor rule"
Nasdaq Listing Rule 5635(b) is an exchange rule that requires a listed company to get shareholder approval before issuing shares or securities that can convert into voting stock when the proposed issue would substantially increase voting power or dilute existing ownership (commonly measured by a 20% threshold). Investors care because the rule limits sudden dilution or shifts in control — like needing neighbor approval before adding a large structure that changes everyone’s influence and property view.
beneficial ownership financial
"the holder would own more than 4.99%, 9.99% or 19.99% of the Company’s outstanding Common Stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Offering Type shelf
Price Range $0.99 per share and accompanying Warrant

FAQ

What did Outlook Therapeutics (OTLK) announce on August 12, 2026?
Outlook Therapeutics announced a public offering of 55,555,556 shares of common stock and accompanying warrants at $0.99 per unit, under an Underwriting Agreement with Piper Sandler & Co. and BTIG, LLC.

How much capital is Outlook Therapeutics (OTLK) raising in this offering?
Outlook Therapeutics estimates gross proceeds of about $55.0 million, before underwriting discounts, commissions and expenses, and assuming no exercise of the accompanying warrants or additional securities option.

What are the key terms of the Outlook Therapeutics (OTLK) warrants in this deal?
Each warrant is immediately exercisable at an exercise price of $1.10 per share, has customary anti-dilution adjustments, and will expire five years from the date of issuance, subject to ownership limits.

What ownership limits apply to the Outlook Therapeutics (OTLK) warrants?
Holders generally may not exercise warrants if it would cause ownership above 4.99%, 9.99% or 19.99% of outstanding common stock, with changes up to 19.99% allowed on 61 days’ notice, subject to terms.

Did insiders participate in the Outlook Therapeutics (OTLK) offering?
Yes. GMS Ventures and Investments bought 2,525,252 shares and warrants, while CEO Robert Jahr and CFO Lawrence Kenyon bought 151,515 and 101,010 shares and accompanying warrants, respectively, in the offering.

What additional option did Outlook Therapeutics (OTLK) grant to underwriters?
The company granted a 30-day option to purchase up to 8,333,333 additional shares and/or warrants. The underwriters exercised this option with respect to warrants to purchase up to 8,333,333 additional shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001649989 0001649989 2026-08-12 2026-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

 

Date of Report (Date of earliest event reported): August 12, 2026

 

 

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware 001-37759 38-3982704
(State or other jurisdiction
of incorporation) 		(Commission File Number) (IRS Employer Identification No.)

 

111 S. Wood Avenue, Unit #100

Iselin, New Jersey

 08830
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (609) 619-3990

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange
on Which Registered
Common Stock   OTLK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On August 12, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and BTIG, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the public offering (the “Offering”) by the Company of (i) 55,555,556 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), and (ii) accompanying warrants to purchase up to an aggregate of 55,555,556 shares of Common Stock (the “Warrants”) at a combined public offering price of $0.99 per share of Common Stock and accompanying Warrant. The shares of Common Stock and Warrants are immediately separable and will be issued separately.

 

The Offering is scheduled to close on or about August 14, 2026, subject to customary closing conditions.

 

The Company also granted the Underwriters an option for a period of 30 days to purchase up to 8,333,333 additional shares of Common Stock and/or Warrants to purchase up to 8,333,333 additional shares of Common Stock at the public offering price, less the underwriting discounts and commissions. On August 12, 2026, the Underwriters exercised such option with respect to the Warrants to purchase up to 8,333,333 additional shares of Common Stock.

 

The Company estimates that the gross proceeds from the Offering will be approximately $55.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company and excluding any exercise of the underwriter's option to purchase additional securities and assuming no exercise of the accompanying Warrants.

 

Each Warrant will have an initial exercise price per share of $1.10, subject to certain customary adjustments for recapitalizations, stock splits and similar actions. The Warrants will be exercisable immediately and will expire five years from the date of issuance. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Warrant to the extent that, immediately after giving effect to such exercise, the holder would own more than 4.99%, 9.99% or 19.99%, as applicable, of the Company’s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder's election to a lower or higher percentage not in excess of 19.99% (if exceeding such percentage would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days’ notice to the Company subject to the terms of the Warrants.

 

The Offering is being made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-278340) previously filed with the Securities and Exchange Commission (the “SEC”) and a prospectus supplement thereunder.

 

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities arising under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for the purposes of the Underwriting Agreement and as of specific dates, and were solely for the benefit of the parties to the Underwriting Agreement.

 

GMS Ventures and Investments, the Company’s largest stockholder, purchased an aggregate of 2,525,252 shares of Common Stock and accompanying Warrants in the Offering. Robert Jahr, the Company’s Chief Executive Officer, and Lawrence Kenyon, the Company’s Chief Financial Officer, purchased an aggregate of 151,515 and 101,010 shares of Common Stock and accompanying Warrants in the Offering, respectively.

 

The foregoing descriptions of the terms of the Underwriting Agreement and Warrants are each qualified in their entirety by reference to the Underwriting Agreement and form of Warrant, respectively, which are attached as Exhibit 1.1 and Exhibit 4.1 hereto, respectively, and incorporated by reference herein.

 

A copy of the legal opinion of Cooley LLP relating to the validity of the issuance and sale of the securities in the Offering is attached as Exhibit 5.1 hereto.

 

 

 

 

Forward-Looking Statements

 

This report contains forward-looking statements, including, without limitation, statements relating to the Company’s expectations regarding the Offering, the amount of proceeds expected from the Offering and the timing and the completion of the Offering. These forward-looking statements are based upon the Company’s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the Offering and other risks detailed in the Company’s filings with the SEC, including Exhibit 99.1 to the Current Report on Form 8-K filed with the SEC on August 12, 2026, as supplemented by subsequent reports the Company files with the SEC and in the prospectus supplement relating to the Offering. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. The Company undertakes no duty to update such information except as required under applicable law.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
1.1   Underwriting Agreement, dated August 12, 2026, by and among the Company, Piper Sandler & Co. and BTIG, LLC, as representatives of the several underwriters named therein.
4.1   Form of Warrant.
5.1   Opinion of Cooley LLP.
23.1   Consent of Cooley LLP (included in Exhibit 5.1).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Outlook Therapeutics, Inc.
   
Date: August 14, 2026               By: /s/ Lawrence A. Kenyon
    Lawrence A. Kenyon
    Chief Financial Officer

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

6 documents

Other Documents